# ACSM2B

## Overview
The ACSM2B gene encodes the enzyme acyl-CoA synthetase medium chain family member 2B, which is a crucial component of the acyl-CoA synthetase medium-chain family. This enzyme is primarily involved in the activation of medium-chain fatty acids to acyl-CoA, facilitating their subsequent degradation through mitochondrial beta-oxidation. It plays a significant role in the glycine conjugation pathway, essential for metabolizing and detoxifying various substrates, including xenobiotics and medium-chain fatty acids (van2018Analyses). The enzyme is predominantly expressed in the liver, underscoring its importance in liver function and metabolic processes (Boomgaarden2009Comparative). Despite its critical metabolic roles, the specific functions and substrate specificities of ACSM2B remain underexplored, with ongoing research needed to elucidate its full biological and clinical significance (van2018Analyses).

## Function
The ACSM2B gene encodes an enzyme that plays a critical role in the glycine conjugation pathway, which is essential for the metabolism and detoxification of various substrates, including xenobiotics like benzoate and salicylate, as well as medium-chain fatty acids (MCFAs) (van2018Analyses). This enzyme is part of the acyl-CoA synthetase medium-chain family and is involved in the activation of medium-chain fatty acids to acyl-CoA, a crucial step for their subsequent degradation via mitochondrial beta-oxidation (van2018Analyses). 

ACSM2B is highly expressed in the liver, indicating its significant role in liver function and metabolic processes (Boomgaarden2009Comparative). The enzyme's activity is localized in the mitochondria, where it contributes to energy production and metabolic homeostasis by facilitating the conversion of fatty acids into acyl-CoA thioesters (Boomgaarden2009Comparative). Despite its importance, the specific role of ACSM2B in the elimination of salicylate and other substrates remains underexplored, necessitating further research to understand its substrate specificity and the impact of genetic variants on its function (van2018Analyses).

## Clinical Significance
The ACSM2B gene has been implicated in several metabolic disorders due to its role in fatty acid metabolism. Polymorphisms in ACSM2B have been associated with traits of insulin resistance syndrome, hypertension, overweight, and type 2 diabetes mellitus, suggesting its significant role in disease susceptibility (Boomgaarden2009Comparative). A genome-wide association study identified the rs9926388 SNP of ACSM2B as a gout-risk locus, indicating a potential link between ACSM2B and gout through its involvement in ATP production, which is relevant to urate metabolism (Nakayama2020Subtypespecific).

Despite these associations, studies have shown inconsistencies in disease associations, and the exact role of ACSM2B in xenobiotic or medium-chain fatty acid metabolism remains unclear (van2018Analyses). The gene's involvement in the glycine conjugation pathway, crucial for detoxifying substances like benzoate and salicylate, suggests that variations in ACSM2B could influence detoxification processes, potentially leading to adverse health effects (van2018Analyses; Rohwer2021Functional). Further research is needed to fully understand the clinical significance of ACSM2B and its genetic variations.


## References


[1. (Rohwer2021Functional) Johann M. Rohwer, Chantelle Schutte, and Rencia van der Sluis. Functional characterisation of three glycine n-acyltransferase variants and the effect on glycine conjugation to benzoyl–coa. International Journal of Molecular Sciences, 22(6):3129, March 2021. URL: http://dx.doi.org/10.3390/ijms22063129, doi:10.3390/ijms22063129. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms22063129)

[2. (van2018Analyses) Rencia van der Sluis. Analyses of the genetic diversity and protein expression variation of the acyl: coa medium-chain ligases, acsm2a and acsm2b. Molecular Genetics and Genomics, 293(5):1279–1292, June 2018. URL: http://dx.doi.org/10.1007/s00438-018-1460-3, doi:10.1007/s00438-018-1460-3. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00438-018-1460-3)

[3. (Nakayama2020Subtypespecific) Akiyoshi Nakayama, Masahiro Nakatochi, Yusuke Kawamura, Ken Yamamoto, Hirofumi Nakaoka, Seiko Shimizu, Toshihide Higashino, Teruhide Koyama, Asahi Hishida, Kiyonori Kuriki, Miki Watanabe, Toru Shimizu, Keiko Ooyama, Hiroshi Ooyama, Mitsuo Nagase, Yuji Hidaka, Daisuke Matsui, Takashi Tamura, Takeshi Nishiyama, Chisato Shimanoe, Sakurako Katsuura-Kamano, Naoyuki Takashima, Yuya Shirai, Makoto Kawaguchi, Mikiya Takao, Ryo Sugiyama, Yuzo Takada, Takahiro Nakamura, Hiroshi Nakashima, Masashi Tsunoda, Inaho Danjoh, Atsushi Hozawa, Kazuyoshi Hosomichi, Yu Toyoda, Yu Kubota, Tappei Takada, Hiroshi Suzuki, Blanka Stiburkova, Tanya J. Major, Tony R. Merriman, Nagato Kuriyama, Haruo Mikami, Toshiro Takezaki, Keitaro Matsuo, Sadao Suzuki, Tatsuo Hosoya, Yoichiro Kamatani, Michiaki Kubo, Kimiyoshi Ichida, Kenji Wakai, Ituro Inoue, Yukinori Okada, Nariyoshi Shinomiya, and Hirotaka Matsuo. Subtype-specific gout susceptibility loci and enrichment of selection pressure on abcg2 and aldh2 identified by subtype genome-wide meta-analyses of clinically defined gout patients. Annals of the Rheumatic Diseases, 79(5):657–665, April 2020. URL: http://dx.doi.org/10.1136/annrheumdis-2019-216644, doi:10.1136/annrheumdis-2019-216644. This article has 27 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1136/annrheumdis-2019-216644)

[4. (Boomgaarden2009Comparative) Inka Boomgaarden, Christina Vock, Maja Klapper, and Frank Döring. Comparative analyses of disease risk genes belonging to the acyl-coa synthetase medium-chain (acsm) family in human liver and cell lines. Biochemical Genetics, 47(9–10):739–748, July 2009. URL: http://dx.doi.org/10.1007/s10528-009-9273-z, doi:10.1007/s10528-009-9273-z. This article has 36 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10528-009-9273-z)